No Data
No Data
Alumis' Investigational Lead Candidate Supports Superior Profile Than Bristol Myers' Commercialized Drug, Analyst Sees 170% Stock Upside
Takeda Declines to Exercise Option for Wave's WVE-003
Strategic Moves in the Japanese Market: T. Rowe Price Japan Fund's Focus on Takeda Pharmaceutical
J.P. Morgan Maintains Takeda Pharmaceutical(TAK.US) With Hold Rating, Raises Target Price to $14.8
Analysts Offer Insights on Healthcare Companies: Takeda Pharmaceutical Company (TAK), Amgen (AMGN) and Halozyme (HALO)
Joint Venture Company Established for Incubation of Early Drug Discovery Programs; Investment From Takeda, Astellas and Sumitomo Mitsui Banking